Eculizumab May Be Safe in Pregnancy, But Data Are Limited

Eculizumab has been used to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Latest News

Complement C1s Inhibition May Prevent Hemolysis in Cold Agglutinin Disease


Patients who received sutimlimab experienced meaningful increases in hemoglobin levels and normalization of bilirubin levels.

Crizanlizumab Granted Breakthrough Tx for Sickle Cell Pain Crises Prevention


Novartis announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for crizanlizumab (SEG101) for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease.

Erythropoietin-Stimulating Agents for the Treatment of Myelodysplastic Syndrome-Associated Anemia


A systematic literature review showed that erythropoietin-stimulating agents positively influenced outcomes of patients with MDS-associated anemia.

Increase in Rates of Post-Hospitalization Iron-Deficiency Anemia


The long-term outcomes of limiting the frequency of red blood cell transfusions in patients with anemia had not previously been described.

Red Blood Cell Deformability Measured by a Microfluidic Device Coupled to Particle Tracking Software


Researchers developed a new method to measure single cell red blood cell deformability.

Multidisciplinary Care for Sickle Cell Disease May Reduce Maternal and Perinatal Mortality


Researchers assessed 266 pregnant women with and without sickle cell disease in Ghana to determine the effect of a multidisciplinary care strategy.

Allogeneic Hematopoietic Cell Transplantation for Sickle Cell Disease and Thalassemia


Allogeneic hematopoietic cell transplantation was tolerated well by pediatric patients with sickle cell disease and transfusion-dependent thalassemia.

Infections and Immune Reconstitution With Bone Marrow Transplantation in Fanconi Anemia


Results from a study in which patients with Fanconi anemia underwent a reduced intensity conditioning regimen followed by bone marrow transplantation.

Cost of First-Line Eltrombopag to Treat Severe Aplastic Anemia


Eltrombopag plus IST was compared with IST alone in a simulated population of 1 million patients with severe aplastic anemia.

Hydroxyurea as Treatment for Children With Sickle Cell Anemia in Sub-Saharan Africa


The efficacy, safety, and feasibility of using hydroxyurea as a therapeutic agent for sickle cell anemia have not been assessed in many populations.

Sickle Cell Trait May Increase Risk for Some Adverse Clinical Outcomes


Investigators conducted a systematic review of 7083 studies to evaluate the association between sickle cell trait and any of 24 adverse clinical outcomes.

A Novel and Rapid Assay for Sickle Cell Disease Screening


Children born with sickle cell disease in low-resource regions of the world often remain undiagnosed and therefore do not receive appropriate treatment.

New Tablet Strength of Sickle Cell Anemia Treatment Siklos Available

By Diana Ernst, RPh

In addition to the 1000mg tablet, Siklos is also available in 100mg tablets.

Promacta Approved as First-Line Treatment for Severe Aplastic Anemia

By Diana Ernst, RPh

The approval was based on data from a single-arm, open-label sequential cohort study in which patients received Promacta in combination with horse antithymocyte globulin (h-ATG) and cyclosporine.

Anemia May Be Associated With Increased Mortality and Length of Hospital Stay


More than one-third of nonanemic patients admitted to Royal Perth Hospital in Australia developed anemia during their stay.

Patients With Diamond-Blackfan Anemia May Be at Higher Risk for Certain Cancers


Researchers analyzed prospective follow-up data from 702 patients with Diamond-Blackfan anemia for cancer incidence and risk.

Management of Red Blood Cell Exchange in African American Patients With Sickle Cell Disease


Approximately 1 in 500 African Americans in the United States has sickle cell disease.

Anemia Identified as Risk Factor for Contrast-Induced Acute Kidney Injury

By Bryant Moeller

Anemia with a baseline hemoglobin <13 g/dL was associated with a more than 5-fold increased risk for contrast-induced acute kidney injury in patients undergoing coronary angiography.

FDA Approves Epoetin Alfa Biosimilar Retacrit

By Steve Duffy

The approval of Retacrit was based on a review of evidence that included human pharmacokinetic/pharmacodynamic data and clinical immunogenicity data which demonstrated a high degree of similarity between Retacrit and its reference product.

Biomarker Indicates Brain Tissue at Risk for Stroke in Sickle Cell Disease

By Brandon May

Using the infarct heat map, the investigators determined that infarct density was higher in the deep white matter and co-localized with the elevated OEF region in the independent prospective cohort.